Sterling Pharma Solutions, a global contract development and manufacturing organization (CDMO), announced a £1 million expansion project at its Deeside, UK site, which is the company’s dedicated bioconjugation and antibody-drug conjugates (ADCs) facility. The project will increase the current laboratory space from 275 to 419 square meters, and reconfigure the layout to provide the ability to develop and expand areas in the future for additional services. This investment is part of a strategy ...